Dernière mise à jour : 02 septembre 2016
Détails
FichiersGeneric Name:
Ibrutinib
État du projet:
Terminé
Fabricant:
Janssen inc.
Brand Name:
Imbruvica
Gamme de produits:
Examen en vue du remboursement
Indicateur de rendement:
Atteint
Strength:
140 mg capsule
Tumour Type:
Lymphome
Indications:
Lymphome du manteau
Funding Request:
Pour le traitement des patients présentant un lymphome du manteau en rechute ou réfractaire
Review Status:
Complete
Date NOC Issued:
Sponsor:
Janssen inc.
Submission Date:
Submission Deemed Complete:
Priorisation demandée:
Non demandée
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
pERC Meeting:
Final Recommendation Issued:
Fichiers
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
Dernière mise à jour : 02 septembre 2016